Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 9 Motor Activity 7 Prostatic Neoplasms 3 Colorectal Neoplasms 2 Urinary Bladder Neoplasms 1 Rectal Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms 1 Multiple Endocrine Neoplasia Type 1 1 Lymphoma, Follicular 1 Lupus Erythematosus, Systemic 1 Insulin Resistance 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Fatigue 1 Diabetes Mellitus, Type 1 1 Cardiovascular Diseases 1 Cardiotoxicity 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Arthritis, Rheumatoid 1 Anxiety Disorders 1

Interventions

Adalimumab 13 Etanercept 8 Methotrexate 7 Rituximab 6 Abatacept 6 tocilizumab 5 golimumab 5 tofacitinib 4 olokizumab 4 Certolizumab Pegol 4 Tumor Necrosis Factor Inhibitors 3 Infliximab 3 Saline Solution 2 Antirheumatic Agents 2 upadacitinib 1 secukinumab 1 sarilumab 1 mavrilimumab 1 baricitinib 1 Vitamin D 1 Vaccines 1 TACI receptor-IgG Fc fragment fusion protein 1 Syringes 1 Sulfasalazine 1 Sodium Chloride 1 Radioimmunodetection 1 RC-18 1 Pharmaceutical Preparations 1 Lysine Acetyltransferase 5 1 Leflunomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Arthritis, Rheumatoid × High-Intensity Interval Training × Clear all

NCT05215509 2024-02-02

RABEX

Rigshospitalet, Denmark

Phase NA Completed

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡